Creating advanced nanoparticles for targeted drug delivery
Computational Design of Antibody-Drug-Excipient Nanoparticles
This study is exploring new tiny particles that can carry medicine right to the parts of the body that need it most, making treatments safer and more effective, and it's designed for anyone interested in better ways to deliver medications.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11054576 on NIH RePORTER |
What this research studies
This research focuses on developing innovative nanoparticles that can deliver medications directly to specific tissues in the body, enhancing their effectiveness and safety. By utilizing machine learning and novel synthesis techniques, the project aims to create drug-excipient co-aggregates that can carry a higher drug load and be tailored for targeted delivery. The researchers will validate these nanoparticles' targeting capabilities through laboratory and animal testing, ensuring they can effectively reach the intended sites of action.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with conditions that could benefit from targeted drug delivery systems, particularly those requiring innovative therapeutic approaches.
Not a fit: Patients who are not seeking advanced therapeutic options or those with conditions that do not require targeted delivery may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for various conditions by improving how drugs are delivered in the body.
How similar studies have performed: Other research has shown promise in using machine learning and novel nanoparticle designs for drug delivery, indicating a potential for success in this innovative approach.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Reker, Daniel — Duke University
- Study coordinator: Reker, Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.